Incyte agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront in cash plus up to $750 million in sales-based milestones (up to $2.0 billion total), announced June 8, 2026. The deal expands Incyte's hematology portfolio into bleeding disorders via VGA039, a Phase 3 investigational subcutaneous prophylactic antibody for von Willebrand disease — the most common inherited bleeding disorder — with potential to be the first subcutaneous prophylactic option versus current intravenous infusions. Closing expected Q3 2026.
Key facts
AnnouncedJun 08, 2026
Deal value$2.0B
Deal typeAcquisition/Merger
Therapeutic areaHematology (bleeding disorders)
Indicationsvon Willebrand disease (VWD)
Key assetsVGA039
MechanismInvestigational monoclonal antibody; subcutaneous prophylaxis to restore hemostasis in von Willebrand disease